Qing Li

Qing Li

Auto-generated profile, based on publicly available information

Qing Li

Dermatology Hospital, Southern Medical University, Guangzhou 510515, China

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2020 in Oncogene
Verified
Journal Article
Open access
PDF file
WFWinnie Fong
Winnie Fong
QLQing Li
Qing Li
JYJun Yu
Jun Yu
Research about the role of gut microbiome in colorectal cancer (CRC) is a newly emerging field of study. Gut microbiota modulation, with the aim to reverse established microbial dysbiosis, is a novel strategy for prevention and treatment of CRC. Different strategies including probiotics, prebiotics, postbiotics, antibiotics, and fecal microbiota transplantation (FMT) have been employed. Although these strategies show promising results, mechanistically by correcting microbiota composition, modulating innate immune system, enhancing gut barrier function, preventing pathogen colonization and exerting selective cytotoxicity against tumor cells, it should be noted that they are accompanied by risks and controversies that can potentially introduce clinical complications. During bench-to-bedside translation, evaluation of risk-and-benefit ratio, as well as patient selection, should be carefully performed. In view of the individualized host response to gut microbiome intervention, developing personalized microbiome therapy may be the key to successful clinical treatment.

1 December 2017 in Cancer Letters
Verified
Journal Article
Closed access
SYsizhe yu
sizhe yu
YWYu Wang
Yu Wang
LJLi Jing
Li Jing
FCFrancois-xavier Claret
Francois-xavier Claret
QLQing Li
Qing Li
HGHui Guo
Hui Guo

9 September 2024 in Gut
Verified
Journal Article
Open access
PDF file
QZQiming Zhou
Qiming Zhou
LLLinhan Lei
Linhan Lei
JCJunhong Cheng
Junhong Cheng
JCJunyou Chen
Junyou Chen
YDYuyang Du
Yuyang Du
XBXiaowu Bai
Xiaowu Bai
Background: Tumourigenesis in right-sided and left-sided colons demonstrated distinct features. Objective: We aimed to characterise the differences between the left-sided and right-sided adenomas (ADs) representing the early stage of colonic tumourigenesis. Design: Single-cell and spatial transcriptomic datasets were analysed to reveal alterations between right-sided and left-sided colon ADs. Cells, animal experiments and clinical specimens were used to verify the results. Results: Single-cell analysis revealed that in right-sided ADs, there was a significant reduction of goblet cells, and these goblet cells were dysfunctional with attenuated mucin biosynthesis and defective antigen presentation. An impairment of the mucus barrier led to biofilm formation in crypts and subsequent bacteria invasion into right-sided ADs. The regions spatially surrounding the crypts with biofilm occupation underwent an inflammatory response by lipopolysaccharide (LPS) and an apoptosis process, as revealed by spatial transcriptomics. A distinct S100A11+ epithelial cell population in the right-sided ADs was identified, and its expression level was induced by bacterial LPS and peptidoglycan. S100A11 expression facilitated tumour growth in syngeneic immunocompetent mice with increased myeloid-derived suppressor cells (MDSC) but reduced cytotoxic CD8+ T cells. Targeting S100A11 with well-tolerated antagonists of its receptor for advanced glycation end product (RAGE) (Azeliragon) significantly impaired tumour growth and MDSC infiltration, thereby boosting the efficacy of anti-programmed cell death protein 1 therapy in colon cancer. Conclusion: Our findings unravelled that dysfunctional goblet cells and consequential bacterial translocation activated the S100A11-RAGE axis in right-sided colon ADs, which recruits MDSCs to promote immune evasion. Targeting this axis by Azeliragon improves the efficacy of immunotherapy in colon cancer.

25 March 2019 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
LJLi Jing
Li Jing
ZRZhiping Ruan
Zhiping Ruan
HSHaifeng Sun
Haifeng Sun
QLQing Li
Qing Li
LHLili Han
Lili Han
MJMing Jiao
Ming Jiao

1 January 2019 in Theranostics
Verified
Journal Article
Open access
IHIdy H.T. Ho
Idy H.T. Ho
XLXiaodong Liu
Xiaodong Liu
YZYidan Zou
Yidan Zou
TLTaian Liu
Taian Liu
WHWei Hu
Wei Hu
MCMatthew TV Chan
Matthew TV Chan
Rationale: Brain-derived neurotrophic factor (BDNF) is a key mediator in the development of chronic pain. Sortilin is known to interact with proBDNF and regulate its activity-dependent secretion in cortical neurons. In a rat model of inflammatory pain with intraplantar injection of complete Freund's adjuvant (CFA), we examined the functional role of proBDNF-sortilin interaction in dorsal root ganglia (DRG).

30 June 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
TWTao Wu
Tao Wu
XMXiao-An Ma
Xiao-An Ma
GWGuoqing Wang
Guoqing Wang
QLQing Li
Qing Li
MLMiao-Jing Li
Miao-Jing Li
HGHui Guo
Hui Guo
ABO blood types are associated with the prognosis of several malignancies. However, the role of the ABO blood type in hepatocellular carcinoma (HCC) remains elusive. Here, we evaluated the prognostic role of the ABO blood group in 691 HCC patients after hepatectomy by Cox regression analysis. A prognostic nomogram was generated to predict the 3 and 5-year overall survival (OS). A total of 262 HCC patients (37.9%) had blood group O, 199 (28.8%) had blood group A, 165 (23.9%) had blood group B, and 65 (9.4%) had blood group AB. The median OS was 55 months in patients with blood group O, 39 months for blood group A, 34 months for blood group B, and 34 months for blood group AB patients (P = 0.001, log-rank test). There were significant differences in OS between patients with blood groups O and A [hazard ratio (HR) = 1.416; 95% CI, 1.101–1.820;P = 0.007], blood group B (HR = 1.736; 95% CI, 1.333–2.262;P < 0.001), blood group AB (HR = 1.739; 95% CI, 1.210–2.499;P = 0.003) and non-O blood groups (HR = 1.485; 95% CI, 1.204–1.830;P < 0.001). Our constructed nomogram (c-index = 0.687) predicted the prognosis more accurately than the TNM stage alone(c-index = 0.601). In conclusion, non-O blood groups are poor prognostic indicators for HCC following hepatectomy. Our findings justify further external validation in larger cohorts.